Ruqin Chen @chenr

Medical Oncologist specialized in GU oncology and Melanoma@mayo clinic Jacksonville, FL Joined December 2008

Tweets

55
Followers

18
Following

100
Likes

10

Ruqin Chen @chenr

5 years ago

69 M smoker with recurrent metastatic NSCLC and refractory ITP. Plt 23k. PD-L1 20%. What treatment to give?

0 0 0 0 0

Level of IL-6 may predict respiratory failure in hospitalized #COVID-19 patients.Various clinical reports suggest that anti-IL-6 could be a valuable tool tomanage such patients (no randomized data yet but trials ongoing). medrxiv.org/content/10.110… sciencedirect.com/science/articl…

6 115 219 0 12

Download Image

Ruqin Chen @chenr

6 years ago

First, testing, testing, testing. Second, protection and prevention. Third, appropriate treat the patients. Help our patients and fight the virus!

0 0 0 0 0

Roy Herbst @DrRoyHerbstYale

7 years ago

Dr. Jennifer Wargo @MDAndersonNews speaking now @YaleCancer @YaleIBIO @YaleMed at our immune-oncology symposium. Biomarkers for immune response! Tissue is the issue and the scoop is in the poop... importance of microbiome @politikaterina

0 7 22 0 1

Download Image

d.planchard @dplanchard

7 years ago

Impressive evolution of therapeutic options in squamous NSCLC with IO @Annals_Oncology @myESMO @peters_solange

1 58 90 0 8

Download Image

IASLC @IASLC

7 years ago

Our President-Elect, Dr. Tetsuya Mitsudomi of Kindai University, presents his take home messages for the future of targeted therapies at the morning plenary at #WCLC2018. #LCSM #TargetedTherapies #LungCancer

0 8 17 0 0

Download Image

soria @jsoriamd

7 years ago

Fascinating review describing the future possibilities that CAR-T could bring to infection, autoimmunity & allotransplantation nature.com/articles/s4157…

1 35 55 0 4

Download Image

Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD

7 years ago

☕️ Tepotinib in MET exon 14 skipping MT show a RR of 58%. Most pts treated in 2/3 L, seems to be well tolerated. I continue to be humbled at the availability of newer agents for #NSCLC. Raising the ceiling of #PersonalizedTherapy @IASLC #WCLC2018

1 4 18 0 1

Sandra Ortiz-Cuaran @SandraOrtizCua

7 years ago

Very encouraging data on the activity of Osimertinib + BLU667 in the setting of acquired resistance to osimertinib.

Lecia Sequist, MD, MPH, FASCO @LeciaSequist

7 years ago

Very encouraging data on the activity of Osimertinib + BLU667 in the setting of acquired resistance to osimertinib.

7 36 99 0 4

1 1 1 0 0

Ben Solomon @bensolomon1

7 years ago

Poiziotinib - looking good in EGFR exon 20 mutation positive NSCLC. Amazing single institution trial by John Heymach at MDACC #WCLC2018

1 19 54 0 2

Download Image

Shankar Siva @_ShankarSiva

7 years ago

This is a game-changer: PACIFIC at the plenary #WCLC2018, with compelling OS benefit. New standard of care. Interesting post-hoc analysis suggests PD-L1 < 1% didn’t benefit, Europe approved this way, but only a subgroup analysis? @AstraZeneca #immunoonc #RadOnc @tssmn @MOGA_ORG

3 30 55 0 2

Download Image

Ben Solomon @bensolomon1

7 years ago

@_ShankarSiva @AstraZeneca @tssmn @MOGA_ORG @DrSanjayPopat @TommyJohn00 @cpeedell @finn_corinne @fifimcdrmh @DrewMoghanaki @gerryhanna @JackWestMD @drtclay Agree - approval should be on ITT population. So many caveats with post hoc analysis in limited subset of patients nicely listed in slide from Naiyer Rizvi

1 1 10 0 0

Download Image

Christine Lovly, MD, PhD, FASCO @christine_lovly

7 years ago

Important and exciting news for treatment of locally advanced lung cancer - addition of durvalumab improves overall survival.

H. Jack West, MD, FASCO @JackWestMD

7 years ago

Important and exciting news for treatment of locally advanced lung cancer - addition of durvalumab improves overall survival.

0 21 36 0 0

Download Image

0 1 7 0 0

d.planchard @dplanchard

7 years ago

Nice article to read in JCO of capmatinib plus gefitinib in EGFR and MET NSCLC pts by Yi-Long Wu et al and @danieltanmd @JCO_ASCO

2 5 12 0 0

Download Image

Jarushka Naidoo @DrJNaidoo

7 years ago

Four practice-changing papers in one day for lung cancer. 1. Pembro+chemo shows OS benefit in 1L mSquamous 2. Brigatinib has a PFS benefit in ALK+ 1L vs. Criz 3. Chemo+Atezo shows OS benefit in 1L ES SCLC 4. Durva shows OS benefit in stage III NSCLC. Now to dissect it all #LCSM

1 28 74 0 1

Download Image

NEJM @NEJM

7 years ago

A 26-year-old man presented with a 3-day history of fever, dry cough, and nonpruritic rash. A physical exam was notable for crackles on the left side of the chest and a macular, targetoid rash on his hands and feet, including the palms and soles. What is the diagnosis?